바로가기메뉴

본문 바로가기 주메뉴 바로가기
 
 

logo

  • ENGLISH
  • P-ISSN1226-6396
  • E-ISSN2234-4942
  • KCI

Efficacy and Safety of Banhahubak-Tang for Depression Treatment: Study Protocol for a Randomized, Waitlist-Controlled Trial

Efficacy and Safety of Banhahubak-Tang for Depression Treatment: Study Protocol for a Randomized, Waitlist-Controlled Trial

동의신경정신과학회지 / Journal of Oriental Neuropsychiatry, (P)1226-6396; (E)2234-4942
2022, v.33 no.4, pp.389-400
https://doi.org/10.7231/jon.2022.33.4.389
Seung-Ho, Lee (Department of Clinical Korean Medicine, Graduate School, Kyung Hee University)
Yunna, Kim (Department of Clinical Korean Medicine, Graduate School, Kyung Hee University)
Dohyung, Kwon (Department of Clinical Korean Medicine, Graduate School, Kyung Hee University)
Seung-Hun, Cho (College of Korean Medicine, Kyung Hee University)

Abstract

Objectives: Depression is a highly prevalent disease, and the market for antidepressant drugs continues to grow at a steady rate. Although current antidepressants are reported to be effective, because of their low remission rate and side effects, new antidepressants are needed. The use of Banhahubak-tang (BHT) to treat the symptoms of depression is supported by experimental evidence. The proposed study will evaluate the efficacy and safety of BHT in treating depression. Methods: A randomized, waitlist-controlled, parallel clinical trial will be conducted to assess the efficacy of BHT in depression. A total of 84 participants with depression will be randomized into the intervention group or waitlist-control group at a 1:1 ratio. Patients in the intervention group will be administered BHT three times a day for four weeks and followed up for four more weeks after therapy completion. Patients in the waitlist-control group will undergo the same intervention and follow-up after a four-week waiting period. The primary outcome is change in the Korean version of the Hamilton Depression Rating Scale (K-HDRS) scores for major depressive disorders after four weeks. The secondary outcomes include scores on the K-HDRS, Korean Symptom Check List 95 (KSCL-95), Insomnia Severity Index (ISI), State-Trait Anxiety Inventory-Korean version (STAI-K), State-Trait Anger Expression Inventory-Korean version (STAXI-K), and the Instrument on Pattern Identifications for Depression and EuroQol-5 Dimension (EQ-5D). Conclusions: This trial will provide high-quality clinical evidence of the efficacy and safety of BHT in the management of depression.

keywords
Major depressive disorder, Banhahubak-tang, Herbal medicine, Randomized controlled trial, Protocol

동의신경정신과학회지